TrialBritish journal of haematology2021
Newly diagnosed and previously treated multicentric Castleman disease respond equally to siltuximab.
Frits van Rhee et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this papercites it